IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$16.16 USD
-1.07 (-6.21%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.40 +0.24 (1.49%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
IGM Biosciences, Inc. [IGMS]
Reports for Purchase
Showing records 1 - 20 ( 93 total )
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-Monthly Check-Up- September 2024
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- Going for the Gold Medal: Cell Therapy in Autoimmune Disease
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q:24 Financials; Aplitabart to 1Q:25 by Popular Demand
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Sanofi Alliance Now Focused on Immunology/Inflammation; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2023 Financials Reported; Reiterate Neutral; Adjusting PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; Possible Aplitabart Update by YE:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Day 3 Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Re-Prioritized; Downgrading to Neutral With $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for IGMS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Datasets Expected; 3Q23 Financials; Lowering PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Checking in on Aplitabart, Imvotamab
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R